2.72

1.49% 0.04

After Hours: 2.76 0.04 +1.47%

Acumen Pharmaceuticals Inc (ABOS)

Overview News Price History Option Chain Financials Discussions Forecast

Acumen Pharmaceuticals Inc stock is traded at $2.72, with a volume of 345.25K. It is up +1.49% in the last 24 hours and down -16.82% over the past month. Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Previous Close:

$2.68

Open:

$2.68

24h Volume:

345.25K

Relative Volume:

0.41

Market Cap:

$196.42M

Revenue:

Net Income/Loss:

$-121.34M

P/E Ratio:

-1.3576

EPS:

-2.0035

Net Cash Flow:

$-115.63M

1W Performance:

+5.43%

1M Performance:

-16.82%

6M Performance:

+19.30%

1Y Performance:

+159.05%

1-Day Range:

$2.635

$2.74

1-Week Range:

$2.45

$2.74

52-Week Range:

$0.8551

$3.60

Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile

Name

Acumen Pharmaceuticals Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

617-344-4190

Address

1210-1220 WASHINGTON STREET, NEWTON

Employee

Twitter

Next Earnings Date

2026-03-26

Latest SEC Filings

ABOS's Discussions on Twitter

Compare ABOS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABOS Acumen Pharmaceuticals Inc	2.72	193.53M	0	-121.34M	-115.63M	-2.0035
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-17-25	Initiated	Citigroup	Buy
Jul-26-24	Initiated	Citigroup	Buy
Dec-12-23	Initiated	Deutsche Bank	Buy
Jul-20-23	Resumed	BofA Securities	Buy
May-18-23	Initiated	Cantor Fitzgerald	Overweight
Jul-15-22	Initiated	BTIG Research	Buy
Jun-30-22	Initiated	H.C. Wainwright	Buy
Jan-21-22	Upgrade	BofA Securities	Neutral → Buy
Jul-26-21	Initiated	BofA Securities	Neutral
Jul-26-21	Initiated	Credit Suisse	Outperform
Jul-26-21	Initiated	Stifel	Buy
Jul-26-21	Initiated	UBS	Buy

View All

Acumen Pharmaceuticals Inc Stock (ABOS) Latest News

Apr 13, 2026

Aug Selloffs: Is Acumen Pharmaceuticals Inc a strong candidate for buy and hold2026 Chart Watch & Safe Capital Allocation Plans - baoquankhu1.vn

Apr 13, 2026

Chart Watch: What is the earnings history of Acumen Pharmaceuticals IncMarket Risk Report & AI Forecasted Entry and Exit Points - baoquankhu1.vn

Apr 13, 2026

Apr 11, 2026

Aug Chart Watch: What is the earnings history of Acumen Pharmaceuticals IncGDP Growth & Short-Term High Return Strategies - baoquankhu1.vn

Apr 11, 2026

Apr 10, 2026

ABOS Forecast, Price Target & Analyst Ratings | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill

Apr 10, 2026

Apr 07, 2026

James B. Murray Jr. discloses 3.61M shares in Acumen Pharmaceuticals (NASDAQ: ABOS) - Stock Titan

Apr 07, 2026

ABOS Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 07, 2026

Apr 06, 2026

Meme Stocks: Is Acumen Pharmaceuticals Inc being accumulated by smart moneyPortfolio Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn

Apr 06, 2026

ABOS Technical Analysis | Trend, Signals & Chart Patterns | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill

Apr 06, 2026

Apr 04, 2026

Acumen Pharmaceuticals’ Earnings Call: Promise Amid Pressure - TipRanks

Apr 04, 2026

Apr 03, 2026

Acumen Pharmaceuticals (ABOS) loses 33.6% in 4 weeks, here's why a trend reversal may be around the corner - MSN

Apr 03, 2026

Earnings Call Summary | Acumen Pharmaceuticals(ABOS.US) Q4 2025 Earnings Conference - 富途牛牛

Apr 03, 2026

Apr 02, 2026

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2025 Earnings Call Transcript - Insider Monkey

Apr 02, 2026

[EFFECT] Acumen Pharmaceuticals, Inc. SEC Filing - Stock Titan

Apr 02, 2026

Apr 01, 2026

Acumen Pharmaceuticals (NASDAQ: ABOS) registers 10.83M resale shares - Stock Titan

Apr 01, 2026

Is Acumen Pharmaceuticals (ABOS) stock outpacing its medical peers this year? - MSN

Apr 01, 2026

ABOS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 01, 2026

Mar 31, 2026

Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding - MSN

Mar 31, 2026

Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - finance.yahoo.com

Mar 31, 2026

Mar 30, 2026

Aug Final Week: Can Acumen Pharmaceuticals Inc reach resistance levels soon - baoquankhu1.vn

Mar 30, 2026

Acumen Pharmaceuticals (ABOS) Drops 33.6% Over the Past Month, Reasons Suggest a Potential Turnaround Could Be Imminent - Bitget

Mar 30, 2026

Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Mar 30, 2026

Should I buy Acumen Pharmaceuticals (ABOS) - Zacks Investment Research

Mar 30, 2026

Mar 29, 2026

Acumen Pharmaceuticals (NASDAQ:ABOS) Rating Increased to Hold at Wall Street Zen - MarketBeat

Mar 29, 2026

Mar 27, 2026

Acumen Pharmaceuticals files to sell 10.83M shares of common stock for holders - MSN

Mar 27, 2026

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Mar 27, 2026

Acumen Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - finance.yahoo.com

Mar 27, 2026

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Mar 27, 2026

Acumen Pharmaceuticals Reports 2025 Financial Results and Advances Alzheimer’s Drug Pipeline with Phase 2 ALTITUDE-AD Study and Enhanced Brain Delivery Program - Minichart

Mar 27, 2026

Mar 26, 2026

10.8M Acumen shares registered for resale (NASDAQ: ABOS) - stocktitan.net

Mar 26, 2026